newsfilter
← Latest News
GlobeNewswire·

Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

  • Aligos Therapeutics entered an exclusive license agreement with Xiamen Amoytop Biotech Co., Ltd. to develop & commercialize pevifoscorvir sodium for chronic HBV infection in Greater China.
  • Aligos will receive an upfront payment of $25M USD & is eligible for up to $420M USD in clinical, regulatory, & sales milestones plus tiered high single-digit royalties.
  • Aligos retains all development & commercialization rights for the drug in the US, Europe, South Korea, Japan, & other global markets.
  • Aligos will retain the right to conduct clinical trials in Greater China while Amoytop funds the regional development program.
  • The agreement is expected to extend Aligos' cash runway into the fourth quarter of 2026 based on current operating plans.
  • Pevifoscorvir sodium is a capsid assembly modulator currently in the Phase 2 B-SUPREME study with a second interim analysis expected in the second half of 2026.
  • Transaction closing is conditional on Amoytop shareholder approval, which is anticipated within 30 days.
  • Amoytop is a leading Chinese pharmaceutical company with commercially approved therapeutics, including PEGBING ® , for treating chronic HBV infection.